Australia's most trusted
source of pharma news
Posted 29 October 2024 AM
The Office of Gene Technology Regulator (OGTR) has deemed a proposed clinical trial of genetically modified (GM) bacteriophages poses "negligible risks" with a consultation now open to inform its final decision on whether to issue a licence.
The Western Sydney Local Health District applied for a licence to administer GM bacteriophages, alone or in combination with non-GM bacteriophage therapy for the treatment of patients with mycobacterial infections in April before being announced by the regulator in July.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.